103 related articles for article (PubMed ID: 12198218)
1. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal.
Lucksiri A; Scott MK; Mueller BA; Hamburger RJ; Sowinski KM
Nephrol Dial Transplant; 2002 Sep; 17(9):1649-54. PubMed ID: 12198218
[TBL] [Abstract][Full Text] [Related]
2. Effects of dialysis membrane on intradialytic vancomycin administration.
Scott MK; Macias WL; Kraus MA; Clark WR; Carfagna MA; Mueller BA
Pharmacotherapy; 1997; 17(2):256-62. PubMed ID: 9085316
[TBL] [Abstract][Full Text] [Related]
3. A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear).
Allawati H; Dallas L; Nair S; Palmer J; Thaikandy S; Hutchison C
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32408589
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
[TBL] [Abstract][Full Text] [Related]
5. Removal of vancomycin administered during dialysis by a high-flux dialyzer.
Nyman HA; Agarwal A; Senekjian HO; Leypoldt JK; Cheung AK
Hemodial Int; 2018 Jul; 22(3):383-387. PubMed ID: 29380499
[TBL] [Abstract][Full Text] [Related]
6. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.
Welage LS; Mason NA; Hoffman EJ; Odeh RM; Dombrouski J; Patel JA; Swartz RD
J Am Soc Nephrol; 1995 Oct; 6(4):1284-90. PubMed ID: 8589298
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers.
Scott MK; Mueller BA; Clark WR
Nephrol Dial Transplant; 1997 Dec; 12(12):2647-53. PubMed ID: 9430866
[TBL] [Abstract][Full Text] [Related]
8. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers.
Sowinski KM; Mueller BA; Grabe DW; Manley HJ; Frye RF; Bailie GR; Marx MA
Am J Kidney Dis; 2001 Apr; 37(4):766-76. PubMed ID: 11273877
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration.
De Bock V; Verbeelen D; Maes V; Sennesael J
Nephrol Dial Transplant; 1989; 4(7):635-9. PubMed ID: 2510061
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
[TBL] [Abstract][Full Text] [Related]
11. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin during the Last Hour of the Hemodialysis Session: A Pharmacokinetic Analysis.
Ghouti-Terki L; Chasseuil E; Rabot N; Paintaud G; François M; Birmelé B; Darrouzain F; Büchler M; Halimi JM; Ternant D
Nephron; 2017; 135(4):261-267. PubMed ID: 28152540
[TBL] [Abstract][Full Text] [Related]
13. Falsely elevated serum vancomycin concentrations in hemodialysis patients.
Follin SL; Mueller BA; Scott MK; Carfagna MA; Kraus MA
Am J Kidney Dis; 1996 Jan; 27(1):67-74. PubMed ID: 8546140
[TBL] [Abstract][Full Text] [Related]
14. Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.
Zoer J; Schrander-van der Meer AM; van Dorp WT
Pharm World Sci; 1997 Aug; 19(4):191-6. PubMed ID: 9297732
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique.
Peckman HJ; Dupuis RE; Sawyer WT; Brouwer KL; Cross RE
Ther Drug Monit; 1996 Dec; 18(6):647-53. PubMed ID: 8946660
[TBL] [Abstract][Full Text] [Related]
16. [Measurements of vancomycin concentrations in the blood - a method of personalization the antibiotic therapy in patients with chronic kidney disease].
Pondel J; Krajewski P; Królikowska N; Tobiasz A; Augustyniak-Bartosik H; Hurkacz M
Pol Merkur Lekarski; 2017 Apr; 42(250):145-150. PubMed ID: 28530212
[TBL] [Abstract][Full Text] [Related]
17. Clearance of vancomycin during high-efficiency hemodialysis.
Klansuwan N; Ratanajamit C; Kasiwong S; Wangsiripaisan A
J Med Assoc Thai; 2006 Jul; 89(7):986-91. PubMed ID: 16881431
[TBL] [Abstract][Full Text] [Related]
18. Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure.
Kihara M; Ikeda Y; Fujita H; Tamura K; Yabana M; Takagi N; Umemura S; Ishii M
Blood Purif; 1996; 14(1):20-5. PubMed ID: 8718561
[TBL] [Abstract][Full Text] [Related]
19. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
[TBL] [Abstract][Full Text] [Related]
20. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
Schaedeli F; Uehlinger DE
Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
